{
    "id": 1230,
    "fullName": "IDH1 R132S",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "IDH1 R132S lies within the active site of the Idh1 protein (PMID: 19228619). R132S confers a gain of function to Idh1, as indicated by increased conversion of alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) in cell culture (PMID: 19935646, PMID: 21326614).",
            "references": [
                {
                    "id": 486,
                    "pubMedId": 19228619,
                    "title": "IDH1 and IDH2 mutations in gliomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19228619"
                },
                {
                    "id": 2755,
                    "pubMedId": 21326614,
                    "title": "2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21326614"
                },
                {
                    "id": 487,
                    "pubMedId": 19935646,
                    "title": "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19935646"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3417,
        "geneSymbol": "IDH1",
        "terms": [
            "IDH1",
            "HEL-216",
            "HEL-S-26",
            "IDCD",
            "IDH",
            "IDP",
            "IDPC",
            "PICD"
        ]
    },
    "variant": "R132S",
    "createDate": "07/31/2014",
    "updateDate": "03/22/2018",
    "referenceTranscriptCoordinates": {
        "id": 143865,
        "transcript": "NM_005896",
        "gDna": "chr2:g.208248389G>T",
        "cDna": "c.394C>A",
        "protein": "p.R132S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16891,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 21.6% (27/125), CR with partial hematological recovery (CRh) in 8.8% (11/125), and overall response (OR) in 41.6% (52/125) of patients with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test (PMID: 29860938; NCT02074839).",
            "molecularProfile": {
                "id": 5018,
                "profileName": "IDH1 R132S"
            },
            "therapy": {
                "id": 1491,
                "therapyName": "Ivosidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11753,
                    "pubMedId": 29860938,
                    "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860938"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15476,
                    "pubMedId": null,
                    "title": "Tibsovo (ivosidenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16894,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial that supported FDA approval, Tibsovo (ivosidenib) treatment resulted in complete remission (CR) in 28.6% (8/28), CR with partial hematological recovery (CRh) in 14.3% (4/28) of patients age 75 or older with untreated acute myeloid leukemia harboring a susceptible IDH1 mutation (R132C/G/H/L/S) as detected by an FDA-approved test, with a median treatment duration of 4.3 months (PMID: 29860938; NCT02074839).",
            "molecularProfile": {
                "id": 5018,
                "profileName": "IDH1 R132S"
            },
            "therapy": {
                "id": 1491,
                "therapyName": "Ivosidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11753,
                    "pubMedId": 29860938,
                    "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29860938"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15476,
                    "pubMedId": null,
                    "title": "Tibsovo (ivosidenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7348,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",
            "molecularProfile": {
                "id": 5018,
                "profileName": "IDH1 R132S"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6322,
                    "pubMedId": 27231123,
                    "title": "Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27231123"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10940,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132S in culture (PMID: 28232670).",
            "molecularProfile": {
                "id": 5018,
                "profileName": "IDH1 R132S"
            },
            "therapy": {
                "id": 5698,
                "therapyName": "BAY1436032",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8943,
                    "pubMedId": 28232670,
                    "title": "Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28232670"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7347,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",
            "molecularProfile": {
                "id": 5018,
                "profileName": "IDH1 R132S"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4928,
                "name": "intrahepatic cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6322,
                    "pubMedId": 27231123,
                    "title": "Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27231123"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5018,
            "profileName": "IDH1 R132S",
            "profileTreatmentApproaches": [
                {
                    "id": 17017,
                    "name": "IDH1 Inhibitor",
                    "profileName": "IDH1 R132S"
                },
                {
                    "id": 17016,
                    "name": "IDH Inhibitor (Pan)",
                    "profileName": "IDH1 R132S"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 143865,
            "transcript": "NM_005896",
            "gDna": "chr2:g.208248389G>T",
            "cDna": "c.394C>A",
            "protein": "p.R132S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 143866,
            "transcript": "NM_001282386",
            "gDna": "chr2:g.208248389G>T",
            "cDna": "c.394C>A",
            "protein": "p.R132S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 143867,
            "transcript": "NM_001282387",
            "gDna": "chr2:g.208248389G>T",
            "cDna": "c.394C>A",
            "protein": "p.R132S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}